Novartis Japan Files Application For Orally Disintegrating Exforge
This article was originally published in PharmAsia News
Executive Summary
Novartis filed an application in Japan for the approval of an orally disintegrating version of its ARB and calcium channel blocker combination Exforge (valsartan/amlodipine) for the treatment of hypertension.